Funding round brings in $20M for Alzheimer's drug developer

05/24/2013 | MedCityNews.com

Acumen Pharmaceuticals has pulled in $20 million in a Series A funding round from BVF Partners, NeuroVentures Fund and other investors. Proceeds will go toward preclinical development of the firm's Alzheimer's disease drug candidate, an antibody that targets soluble oligomers of the amyloid beta peptide in the brain.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI